ISSN 1866-8836
Клеточная терапия и трансплантация

Priming of the bone marrow grafts by filgrastim in related and haploidentical transplantations with posttransplantation cyclophosphamide

Dmitrii E. Pevtcov, Ivan S. Moiseev, Viktoria A. Dubkova, Elena V. Babenko, Maria A. Estrina, Irina I. Kulagina, Olesya V. Paina, Tatyana A. Bikova, Ludmila S. Zubarovskaya, Boris V. Afanasyev
R. M. Gorbacheva Memorial Institute of Oncology, Hematology and Transplantation, Chair of Hematology, Transfusiology and Transplantology, Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russian Federation



Using bone marrow (BM) as the graft source results in lower graft-versus-host disease incidence. Nonetheless achieving adequate CD34+ cell count might be complicated in cases of donor-recipient weight differences. Priming with G-CSF may partly solve this problem. A number of studies were published demonstrating increased CD34+ cell count and faster engraftment. Also there are reports of immunomodulatory effect of BM priming. It is not known if this strategy works with posttransplant cyclophosphamide (PTCy) graftversus-host disease (GVHD) prophylaxis.

Patients and methods

41 consecutive patients with primed BM graft and PTCy-based GVHD prophylaxis were included in the analysis. They were pair-matched 1:1 to non-primed graft recipients also with PTCy-based GVHD prophylaxis. The criteria for matching were type of the donor, age of the recipient, underlying disease and disease status at the time of SCT. There was significant differences between groups in any of the clinical parameters tested (p>0.18). Priming was performed with three injections of filgrastim 5-7 mcg/kg daily for 3 days prior to BM harvesting. Median recipient age was 14 years (range 1-58). 76% of patients received the graft from haplo donor, 24% – from matched related donor. 46% of patients had acute lymphoblastic leukemia, 38% – acute myeloid leukemia, 2% – aplastic anemia, 14% – other malignancies. 38% were classified as salvage patients. 29% received myeloablative conditioning, 71% – reduced intensity.


The yield of CD34+ x10^6 cells/kg of recipient weight was only non-significantly higher in the priming group: 6.5±3.4 vs 5.4±2.8, p=0.15. The yield of CD34+ cells per kg of donor weight was also not different: 4.3±4.0 vs 4.3±5.8, p=0.55. There was no difference in the incidence of primary graft failure (22% vs 24%, p=0.79). Median time to neutrophil (21 vs 24 days, p=0.008) was shorter in non-priming group, while time to platelet engraftment was not different (19 vs 23 days, p=0.38). Median follow-up was 29 months (range 9-50). There was no differences between priming and non-priming groups in the incidence of acute grade II-IV GVHD (15% vs 5%, p=0.17), moderate and severe chronic GVHD (19% vs 15%, p=0.55), 2-years non-relapse mortality (17% vs 22%, p=0.58), relapse incidence (44% vs 51%, p=0.53), overall survival (51% vs 39%, p=0.38), event-free survival (39% vs 27%, p=0.41) and GVHD- elapse-free survival (22% vs 23%, p=0.39).


The presented priming schedule did not lead to improved clinical outcomes after PTCy-based GVHD prophylaxis. Also it might be associated with delayed engraftment with PTCy prophylaxis. Nonetheless, these results should be interpreted with caution, because this study included large proportion of pediatric patients and patients with active disease. The results should be confirmed in well-designed prospective clinical trials.


Hematopoietic stem cell transplantation, bone marrow priming, cyclophosphamide posttransplant, GVHD prophylaxis.

Volume 6, Number 3
09/27/2017 10:19:34 pm

Download PDF version

Back to the list